Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Branched 3-phenylpropionic sgc modulators: BayerRecent Research Landscape

Inadequate vasodilation in female heart failure patients leads to high hospitalization costs, which is mitigated through targeted soluble guanylate cyclase activation. This specific chemical scaffold provides the molecular control necessary to restore cyclic GMP signaling.

What technical problems is Bayer addressing in Branched 3-phenylpropionic sgc modulators?

Insufficient therapeutic bioavailability

(37)evidences

Poor solid-state stability and low solubility of therapeutic compounds limit clinical efficacy. Improving crystalline forms prevents degradation and ensures predictable pharmacokinetic profiles.

Upper airway collapse

(13)evidences

The cluster addresses the physical obstruction of the respiratory tract during sleep. Preventing this mechanical failure maintains blood oxygen saturation and prevents sleep fragmentation.